Galvus 50 mg 28 tablets

Trade name:

Galvus

Galvus

Properties

Hypoglycemic agent. Vildagliptin is a representative of the class of pancreatic islet stimulants that selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). Rapid and complete inhibition of DPP-4 activity (>90%) causes an increase in both basal and food-stimulated secretion of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) from the intestine into the systemic circulation throughout the day.

Indications

Type 2 diabetes mellitus: as monotherapy in combination with diet and exercise; as part of a two-component combination therapy with metformin, sulfonylurea derivatives, thiazolidinedione or insulin in case of failure of diet therapy, exercise and monotherapy with these drugs.

Dosage and administration

The optimal dosage regimen is determined by the doctor. Compliance of the dosage form of a particular drug with indications for use and dosing regimen should be strictly observed.

The dosage regimen is set individually depending on the effectiveness, tolerability and treatment regimen.

Single dose — 50 mg, daily dose — 100 mg (50 mg 2 times / day).

Contraindications

Hypersensitivity to vildagliptin.

Precautionary measures:

Not recommended for use in patients with severe hepatic impairment, incl. with an increase in ALT or AST activity > 2.5 times higher than ULN.

Side effects

From the digestive system: sometimes — constipation; rarely — liver dysfunction (including hepatitis) of an asymptomatic course; when combined with insulin often — nausea, flatulence, GERD.

From the side of the central nervous system: often — tremor, dizziness, headache.

From the side of metabolism: often — hypoglycemia, weight gain.